These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 7684676)
1. Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty. Barradell LB; McTavish D Drugs; 1993 Apr; 45(4):570-88. PubMed ID: 7684676 [TBL] [Abstract][Full Text] [Related]
2. The histrelin implant: a novel treatment for central precocious puberty. Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137 [TBL] [Abstract][Full Text] [Related]
3. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629 [TBL] [Abstract][Full Text] [Related]
4. Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant. Hirsch HJ; Lahlou N; Gillis D; Strich D; Rosenberg-Hagen B; Chertin B; Farkas A; Hartman H; Spitz IM J Clin Endocrinol Metab; 2010 Jun; 95(6):2841-4. PubMed ID: 20339028 [TBL] [Abstract][Full Text] [Related]
5. Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial. Silverman LA; Neely EK; Kletter GB; Lewis K; Chitra S; Terleckyj O; Eugster EA J Clin Endocrinol Metab; 2015 Jun; 100(6):2354-63. PubMed ID: 25803268 [TBL] [Abstract][Full Text] [Related]
7. Experience with the Histrelin Implant in Pediatric Patients. Eugster EA Endocr Dev; 2016; 30():54-9. PubMed ID: 26683629 [TBL] [Abstract][Full Text] [Related]
8. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Plosker GL; Brogden RN Drugs; 1994 Dec; 48(6):930-67. PubMed ID: 7533699 [TBL] [Abstract][Full Text] [Related]
9. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis. Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027 [TBL] [Abstract][Full Text] [Related]
10. Time to menarche and final height after histrelin implant treatment for central precocious puberty. Gillis D; Karavani G; Hirsch HJ; Strich D J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026 [TBL] [Abstract][Full Text] [Related]
11. Histrelin for central precocious puberty-a single surgeon experience. Rosati S; Maarouf R; Brown K; Poppe M; Parrish D; Haynes J; Lanning D J Surg Res; 2015 Oct; 198(2):355-9. PubMed ID: 25899147 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. Eugster EA; Clarke W; Kletter GB; Lee PA; Neely EK; Reiter EO; Saenger P; Shulman D; Silverman L; Flood L; Gray W; Tierney D J Clin Endocrinol Metab; 2007 May; 92(5):1697-704. PubMed ID: 17327379 [TBL] [Abstract][Full Text] [Related]
13. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. Manasco PK; Pescovitz OH; Feuillan PP; Hench KD; Barnes KM; Jones J; Hill SC; Loriaux DL; Cutler GB J Clin Endocrinol Metab; 1988 Aug; 67(2):368-72. PubMed ID: 3292562 [TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation. Mansfield MJ; Beardsworth DE; Loughlin JS; Crawford JD; Bode HH; Rivier J; Vale W; Kushner DC; Crigler JF; Crowley WF N Engl J Med; 1983 Nov; 309(21):1286-90. PubMed ID: 6415479 [TBL] [Abstract][Full Text] [Related]
15. A single histrelin implant is effective for 2 years for treatment of central precocious puberty. Lewis KA; Goldyn AK; West KW; Eugster EA J Pediatr; 2013 Oct; 163(4):1214-6. PubMed ID: 23809043 [TBL] [Abstract][Full Text] [Related]
16. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060 [TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of central precocious puberty--can final height be improved? German/Dutch Central Precocious Puberty Study Group. Sippell WG Horm Res; 1994; 41 Suppl 2():14-5. PubMed ID: 8088698 [TBL] [Abstract][Full Text] [Related]
18. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638 [TBL] [Abstract][Full Text] [Related]
19. Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty. Ray LA; Eckert GJ; Eugster EA J Pediatr Endocrinol Metab; 2023 Mar; 36(3):309-312. PubMed ID: 36625262 [TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and treatment patterns with histrelin acetate subcutaneous implants vs. leuprolide injections in children with precocious puberty: a real-world study using a US claims database. Silverman LA; Han X; Huang H; Near AM; Hu Y J Pediatr Endocrinol Metab; 2021 Aug; 34(8):961-969. PubMed ID: 34147047 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]